A case of pyoderma gangrenosum responding to high-dose intravenous immunoglobulin therapy

Chinese Medical Journal

Volumn 119, Issue 14, 2006, Pages 1230-1232

  Zhang, Xi Bao ^a   He, Yu Qing ^a   Zhou, Hua ^b   Luo, Quan ^a   Li, Chang Xing ^a  

^a GUANGZHOU INSTITUTE OF DERMATOLOGY   (China)

^b PUMC   (China)

Author keywords

Immunoglobulins; Intravenous; Pyoderma gangrenosum; Treatment

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN; IMMUNOGLOBULIN; MINOCYCLINE; PREDNISOLONE; STEROID; THALIDOMIDE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; PHYSICAL EXAMINATION; PYODERMA GANGRENOSUM; SKIN BIOPSY; SKIN SCAR; TREATMENT DURATION;

EID: 33746329922     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200607020-00019     Document Type: Article

References (14)

1. Von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 1997; 337: 1000-1005.
2. Callen JP. Pyoderma gangrenosum and related disorders. Med Clin North Am 1989;73:1247-1261.
3. Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol 2002;3:149.
4. Fujimoto E, Fujimoto N, Kuroda K, Tajima S. Leukocytapheresis treatment for pyoderma gangrenosum. Br J Dermatol 2004;151:1090-1092.
5. Gupta AK, Shear NH, Sauder DN. Efficacy of human intravenous immune globulin in pyoderma gangrenosum. J Am Acad Dermatol 1995; 32:140-142.
6. Dirschka T, Kastner U, Behrens S, Altmeyer P. Successful treatment of pyoderma gangrenosum with intravenous human immunoglobulin. J Am Acad Dermatol 1998; 39:789-790.
7. Gleichmann US, Otte HG, Korfer R, Stadler R. Post-traumatic pyoderma gangrenosum: combination therapy with intravenous immunoglobulins and systemic corticosteroids. Hautarzt 1999; 50:879-883.
8. Svenson M, Hansen MB, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993;92:2533-2539.
9. Stangel M, Schumacher HC, Ruprecht K, Boegner F, Marx P. Immunoglobulins for intravenous use inhibit TNF alpha cytotoxicity in vitro. Immunol Invest 1997;26: 569-578.
10. Hartung HP, Kieseier B. Intravenous immunoglobulins mechanisms of action. In: Stephen J ed. Intravenous immunoglobulins in dermatology. London UK: Taylor & Francis Group; 2003:12-14.
11. Sawada K, Ohnishi K, Kosaka T. Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther Apher 1997;7:207-211.
12. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokin nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994;139:5-19.
13. Kekow J, Reinhold D, Pap T, Ansorge S. Intravenous immunoglobulins and transforming growth factor beta. Lancet 1998;351:184-185.
14. Aukrust P, MullerF, Svenson M, Nordoy I, Bendtzen K, Froland SS. Administration of intravenous immunoglobulin (IVIg) in vivo-down-regulatory effects on the IL-1 system. Clin Exp Immunol 1999;115:136-143.